Cengiz E.Karaca B.Kucukzeybek Y.Gorumlu G.Gul M.K.Erten C.Atmaca H.Uzunoglu S.Karabulut B.Sanli U.A.Uslu R.2024-07-222024-07-22201015734978http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18465Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose-and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array® (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated C3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers. © Springer Science+Business Media B.V. 2009.EnglishApoptosisCell Line, TumorDNA, ComplementaryDose-Response Relationship, DrugDrug Resistance, NeoplasmDrug Therapy, CombinationEnzyme-Linked Immunosorbent AssayGene Expression ProfilingGene Expression Regulation, NeoplasticGossypolHumansMaleProstatic NeoplasmsTaxoidsTime Factorsdocetaxelgossypolcomplementary DNAdocetaxelgossypoltaxoidapoptosisarticlecancer cell culturecarcinogenesiscell cycle regulationcell metabolismcell viabilityconcentration responsecontrolled studycytotoxicityDNA repairdose time effect relationdown regulationdrug potentiationgene expression profilinghumanhuman cellmalepolymerase chain reactionprostate cancerapoptosisdose responsedrug combinationdrug effectdrug resistanceenzyme linked immunosorbent assaygene expression regulationgeneticsphysiologyprostate tumortimetumor cell lineArticle10.1007/s11033-009-9501-y